A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine. 1986

S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi

Antibody persistence was measured in 39 children in an open community 12-13 years after immunization against measles with further attenuated live vaccine, Biken CAM. Serum samples of the children taken every two or three years after vaccination had higher, lower, or the same HI antibody titers as those in samples taken 6 weeks after vaccination. These differences reflected a decrease in the titer in some children and subclinical natural reinfection in others. However, all the children still retained detectable antibody in 12 or 13 years after vaccination, indicating long-term persistence of immunity after immunization with Biken CAM vaccine. For evaluation of the protective efficacy of the vaccine, matched controls were studied during the same period. Serological examination revealed that 97.5% of the controls were infected with measles and contracted the disease. In contrast, none of the vaccinees developed clinical infection after close contact with measles patients.

UI MeSH Term Description Entries
D008457 Measles A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM. Rubeola
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D008459 Measles virus The type species of MORBILLIVIRUS and the cause of the highly infectious human disease MEASLES, which affects mostly children. Edmonston virus
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated

Related Publications

S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
June 1982, Biken journal,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
September 1970, Biken journal,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
September 1970, Biken journal,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
August 2000, Revista de saude publica,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
January 1965, Archiv fur die gesamte Virusforschung,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
September 1970, Biken journal,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
March 1971, Biken journal,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
January 1964, Paediatrica Indonesiana,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
January 1967, Progress in immunobiological standardization,
S Isomura, and T Morishima, and K Nishikawa, and N Hanada, and M Rahman, and M Terashima, and S Kido, and S Ueda, and M Takahashi
June 1963, Pediatrics,
Copied contents to your clipboard!